The value of various forms of regional administration of cisplatin in the treatment of liver metastases in the rat.
Tumour growth was induced exclusively in the livers of 40 F1 WagRij/BN rats (eight groups of five rats each) by intraportal inoculation of a squamous cell carcinoma. Four groups were treated by infusion of cisplatin (to which the tumour was sensitive) for a total of three doses of 3 mg/kg body weight at 5-day intervals and one group served as control. Treatment was given systemically, via the hepatic artery, via the portal vein and the hepatic artery simultaneously, and via the portal vein. The untreated animals had a mean survival time of 119 days, as opposed to 211, 249, 192 and 239 days for the treated animals. The animals treated via the hepatic artery lived significantly longer on average (P = 0.035) than those treated systemically or via the portal vein. The combination of intraportal and intra-arterial infusion had no advantage over infusion via the hepatic artery alone. The route of administration does not appear to influence the general toxicity of cisplatin.
D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D007261:Infusions, Intra-Arterial; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D002945:Cisplatin